Stockscreener 앱 받기
124.29
2.32%
2.82
시간 외 거래:
124.78
0.49
+0.39%
전일 마감가:
$121.47
열려 있는:
$121.19
하루 거래량:
24.23M
Relative Volume:
3.23
시가총액:
$154.20B
수익:
$29.05B
순이익/손실:
$8.11B
주가수익비율:
19.25
EPS:
6.4563
순현금흐름:
$9.16B
1주 성능:
+3.23%
1개월 성능:
-2.95%
6개월 성능:
+15.08%
1년 성능:
+36.45%
1일 변동 폭
$121.00
$126.27
1주일 범위
$118.17
$126.27
52주 변동 폭
$88.57
$128.70
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
124.29 | 150.71B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,071.44 | 945.93B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.37 | 501.88B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.82 | 393.81B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
136.06 | 259.56B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
101.09 | 249.91B | 63.90B | 19.05B | 13.05B | 7.5596 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Forbes Has Listed Gilead as One of America’s Best Employers for Diversity - CSRwire
Portfolio Recap: Will Gilead Sciences Inc. stock outperform value stocksProfit Target & Capital Protection Trading Alerts - ulpravda.ru
Key facts: Gilead shares up 3.3% on positive HIV trial; drug prices to drop - TradingView — Track All Markets
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal - Benzinga
Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open - ts2.tech
Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance
Gilead Sciences Signs Deal With US Government to Lower Drug Costs - marketscreener.com
Gilead agrees to lower drug prices in U.S. under Trump administration deal - Investing.com Australia
Gilead (GILD) Strikes Deal to Cut Drug Costs With U.S. Governmen - GuruFocus
GILEAD reaches three-year pricing agreement with US government - StreetInsider
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans - Business Wire
New Gilead deal will cut costs for some HIV and hepatitis drugs in U.S. - Stock Titan
Gilead Sciences' Yeytuo for Prevention of HIV-1 Infection Approved by UK Regulator - marketscreener.com
Support Test: Is Gilead Sciences Inc. stock oversold or undervaluedEarnings Recap Summary & Daily Technical Stock Forecast Reports - Улправда
Is Gilead Sciences Inc. stock a good choice for value investorsJuly 2025 Movers & Low Risk High Reward Trade Ideas - DonanımHaber
Voya Investment Management LLC Purchases 426,743 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Will GILD's Strong HIV Portfolio Reap Rewards in 2026? - TradingView — Track All Markets
Why Gilead Sciences Inc. stock remains on buy listsWeekly Market Outlook & Stock Timing and Entry Methods - Улправда
Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025) - ts2.tech
Gilead Sciences Promotes In-House Atty To General Counsel - Law360
Gilead Sciences Promotes Veteran Legal Leader to General Counsel - Bloomberg Law News
Gilead Sciences names Keeley Wettan as new general counsel - Investing.com
Gilead Sciences appoints Keeley Wettan as executive vice president - marketscreener.com
NatWest Group plc Trims Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Appoints Keeley Wettan as EVP, General Counsel, Legal & Compliance - Contract Pharma
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance - The Derrick
Czech National Bank Acquires 11,080 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Will Gilead Sciences Inc. stock outperform value stocksExit Point & Safe Entry Zone Tips - Улправда
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know - sharewise.com
Gilead Sciences (GILD) Valuation After Positive Phase 3 Data for Its Bictegravir–Lenacapavir HIV Regimen - Yahoo Finance
Does Gilead Still Offer Value After Its 2025 Surge and Pipeline Progress? - Yahoo Finance
Assenagon Asset Management S.A. Buys 2,169,266 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Insider Sell: Johanna Mercier Sells 3,000 Shares of Gilead Scien - GuruFocus
Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells 3,000 Shares of Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares - MarketBeat
Gilead Sciences Executives Sell Shares - TradingView — Track All Markets
CFO Dickinson Sells 3,000 ($366K) Of Gilead Sciences Inc [GILD] - TradingView — Track All Markets
Gilead's single-tablet HIV combo of bictegravir, lenacapavir passes another late-stage test on way to filings - Fierce Pharma
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal - Yahoo! Finance Canada
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial - BioSpace
Gilead’s experimental HIV treatment meets main goal in late-stage trial - WKZO
Gilead's experimental HIV treatment non-inferior to blockbuster drug in trial - Reuters
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial - European AIDS Treatment Group
Gilead to start demolishing buildings for campus expansion by end of month - The Business Journals
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains - Investing.com
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meet - pharmiweb.com
Wolfe Research Adjusts Gilead Sciences PT to $150 From $140, Maintains Outperform Rating - marketscreener.com
Gilead Sciences Reports Positive Phase 3 ARTISTRY-2 HIV Trial Results - Nasdaq
Gilead (GILD) Hits Key Milestone with ARTISTRY-2 HIV Treatment T - GuruFocus
Gilead Yeztugo HIV combo pill meets goal in second phase 3 trial - Seeking Alpha
Gilead reports positive results for HIV treatment combination By Investing.com - Investing.com South Africa
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.60%
자본화:
|
볼륨(24시간):